Efficacy of ublituximab in clinical practice Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Dec 31, 2025
DOI: https://doi.org/10.24292/01.MS.144311225.2
Keywords:
multiple sclerosis, ublituximab, anti-CD20 antibodies, B lymphocytes

Main Article Content

Adam Stępień
Klinika Neurologii, Wojskowy Instytut Medyczny – Państwowy Instytut Badawczy, Warszawa

Abstract

Multiple sclerosis is a chronic neuroinflammatory disease in which B lymphocytes play a significant role, participating in the process of demyelination and neurodegeneration. The introduction of anti-CD20 monoclonal antibodies has changed the approach to multiple sclerosis treatment, and one of the newest drugs in this group is ublituximab. This drug demonstrates high efficacy in reducing the number of relapses and demyelinating lesions visible on MRI, as confirmed in the ULTIMATE I and II studies. Ublituximab proved more effective than teriflunomide in reducing disease activity, although no significant differences in disability progression were demonstrated. Long-term follow-up data and real-world evidence analyses confirm the therapy’s sustained efficacy and favorable safety profile. Study results also indicate the benefits of early implementation of highly effective treatment in patients with relapsing-remitting multiple sclerosis.

Article Details

Issue
Vol 14 No 4(53) (2025)
Section
Articles

Copyright ? by Medical Education. All rights reserved.

References

1. Brown JW, Pardini M, Brownlee WJ et al. An abnormal periventricular magnetization transfer ratio gradient occurs early in multiple sclerosis. Brain. 2017; 140: 387-8.
2. Kalaitzidis G, Calabresi P. Is Cerebrospinal Fluid Responsible for Innate Immune Cell Activation and Neurotoxicity in Multiple Sclerosis? Neurology. 2021; 96: 649-50. http://doi.org/10.1212/WNL.0000000000011694.
3. Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2019; 9: 3116.
4. Babiker HM, Glode AE, Cooke LS et al. Ublituximab for the treatment of CD20 positive B-cell malignancies. Expert Opin Investig Drugs. 2018; 27(4): 407-12. http://doi.org/10.1080/13543784.2018.1459560.
5. Greenfield AL, Hauser SL. B-cell Therapy for Multiple Sclerosis: Entering an era. Ann Neurol. 2018; 83(1): 13-26. https://doi.org/10.1002/ana.25119.
6. Shinoda K, Li R, Rezk A et al. Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. Proc Natl Acad Sci USA. 2023; 120(3): e2207291120. http://doi.org/10.1073/pnas.2207291120.
7. Norborg H, Asrshed JH, Mannshed J et al. Effect of early highly effective treatment compared to an escalating treatment strategy in multiple sclerosis Mult Scler Relat Disord. 2025; 103: 11.
8. de Sèze J, Maillart E, Gueguen A et al. Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic. Front Immunol. 2023; 14: 1004795. http://doi.org/10.3389/fimmu.2023.1004795.
9. Ancau M, Berthele A, Hemmer B. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. Expert Opin Biol Ther. 2019; 19(8): 829-43.
10. Sellebjerg F, Blinkenberg M, Sorensen PS et al. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. CNS Drugs. 2020; 34(3): 269-80.
11. Fox E, Lovett-Racke AE, Gormley M et al. A phase 2 multicenter study of ubli-tuximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021; 27: 420-9.
12. Alvarez E, Steinman L, Fox EJ et al. Reduced disease progression with ublituximab vs teriflunomide in the phase 3 ULTIMATE I and II studies in relapsing multiple sclerosis. In: Abstracts from the 36th Annual Meeting of the Consortium of Multiple Sclerosis Centers, June 1–4, 2022. National Harbor, MD: Consortium of Multiple Sclerosis Centers. 2022.
13. Steinman L, Fox E, Hartung HP. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2022; 387: 704-14. http://doi.org/10.1056/NEJMoa2201904.
14. Cree B. Long-Term Efficacy and Safety of Ublituximab in Relapsing Multiple Sclerosis: Results from 6 Years of ULTIMATE I and II Open-Label Extension. Presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) | 24-26 September 2025, Barcelona, Spain.
15. Boll C, Hoyt T, Pashley L et al. Real-World Ublituximab Experience at a Single MA Center. Presented at the 2025 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting; February 27-March 1, 2025.